(Total Views: 539)
Posted On: 07/16/2022 7:11:35 PM
Post# of 154902
2nd Quarter Developments
● In October 2021, the Company signed a research agreement with a leading cancer research institution, the University of Texas MD Anderson Cancer Center, to evaluate the potential synergistic therapeutic efficacy of leronlimab in combination with immune checkpoint blockade.
taken from page 35 from here:
https://www.cytodyn.com/investors/sec-filings...30x10q.htm
in addition:
https://www.globenewswire.com/en/news-release...e-ICB.html
notice the word "study"
● In October 2021, the Company signed a research agreement with a leading cancer research institution, the University of Texas MD Anderson Cancer Center, to evaluate the potential synergistic therapeutic efficacy of leronlimab in combination with immune checkpoint blockade.
taken from page 35 from here:
https://www.cytodyn.com/investors/sec-filings...30x10q.htm
in addition:
https://www.globenewswire.com/en/news-release...e-ICB.html
notice the word "study"
(5)
(0)
